AgingResearch.NewsJoin free

AriBio

CompanySouth Korea

AriBio develops one asset, in phase 3 (AR1001 in Alzheimer's disease). Mostly small molecule acting on PDE5A; based in South Korea.

1
Asset
Furthest stage
Phase 3
1
Trial
1
Signal

Pipeline

1

  • AR1001

    Inhibits phosphodiesterase 5, increasing intracellular cyclic GMP signaling.

    Phase 3, Small molecule, PDE5A, Alzheimer's disease

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials1
  • Signals1
  • Similar companies6

Intelligence